MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice
Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by the selective loss of spinal motor neurons (MNs) and concomitant muscle weakness. Mutation of SMN1 is known to cause SMA, and restoring SMN protein levels via antisense oligonucleotide treatment is effective for ameliorati...
Main Authors: | Tai-Heng Chen, Shih-Hsin Chang, Yu-Fu Wu, Ya-Ping Yen, Fang-Yu Hsu, Yen-Chung Chen, Yang Ming, Ho-Chiang Hsu, Yi-Ching Su, Sheng-Tang Wong, Jui-Hung Hung, Shih-Hwa Chiou, Yuh-Jyh Jong, Jun-An Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253123000641 |
Similar Items
-
Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
by: Maren Freigang, et al.
Published: (2021-07-01) -
Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
by: Lars Hendrik Müschen, et al.
Published: (2021-02-01) -
Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children
by: Liyuan Chen, et al.
Published: (2023-12-01) -
Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment
by: Silvia Bonanno, et al.
Published: (2022-08-01) -
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
by: Praveen Thokala, et al.
Published: (2020-10-01)